Tenderwize
Zurück zur Suche

Open-house rebate agreements for Natalizumab IV

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Mar 31, 2027 · 218 days left·Open·Supplies
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Natalizumab, i.v. Darreichungsform, ATC L04AG03

46/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Warum diese Bewertung?

Chance

46 / 100

Komplexität

58 / 100

Risikofaktoren

Submission must be in original form and electronic submission is not allowed.

Only authorised and marketable medicines in Germany may be supplied; if Lauer-Taxe evidence is missing, additional AMIc...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Supply of pharmaceutical products under an open-house rebate agreement for Natalizumab, intravenous dosage form, ATC L04AG03.
  • Non-exclusive contract model with uniform terms for all participants; no individual negotiations.
Vollständige Zusammenfassung anzeigen

Open-house supply arrangement for Natalizumab (IV form, ATC L04AG03) offered by AOK Rheinland-Pfalz/Saarland. The notice states this is a non-exclusive, open-house model with uniform terms, no individual negotiations, and monthly entry possible during a maximum 24-month period. Submission is by original documents, electronic submission is not allowed, and the provided data indicates no contract value was published. The notice also states that children’s medicines listed by BfArM under §35(5a) SGB V are excluded.

Risiken

Submission must be in original form and electronic submission is not allowed.

Only authorised and marketable medicines in Germany may be supplied; if Lauer-Taxe evidence is missing, additional AMIc...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Only authorised and marketable medicines in Germany may be supplied under the contract.

Administrative

  • If the medicine is not listed in Lauer-Taxe at submission time, the bidder must provide an extract from the public AMIce database and, where needed, additional supporting...
  • Submission must be in original form; electronic submission is not allowed.

Auftraggeber

Lose (1)

LOT-0001

Open-house rebate agreements for Natalizumab IV

Single lot covering non-exclusive open-house rebate agreements for medicinal products containing Natalizumab in intravenous dosage form (ATC L04AG03). The buyer states that all interested pharmaceutical companies may join under identical conditions, without selection decision or individual negotiation. The lot excludes medicines listed as children’s medicines under the BfArM list referenced in the notice. Contract duration is up to 24 months, with the earliest start on 2025-06-01 and monthly entry possible; contracts end no later than 24 months after the earliest start date. The lot-level value is not provided.

SuppliesEU fundedElectronic submission

Ort

Eisenberg, Germany

Dauer

May 2025 - May 2027

Kategorie

Pharmaceutical products

Frist

Deadline Mar 31, 2027

Vergabedetails

Veröffentlichungsdatum
10 Apr 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
235853-2025

Dokumente (1)

Ähnliche Ausschreibungen